For the complete report, get in touch with us at : info@netscribes.com Anti-infective pharmaceuticals market in India is the largest contributor to domestic pharmaceutical sales, contributing around 18%. Since India has a huge patient pool, the Indian market is characterized by a huge demand for anti-infective drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, increasing number of vaccine approvals, increase in health insurances and introduction of newer and better drugs is helping the market to grow. The Indian Government, on its part, has introduced some control programmes, undertaken various Private Partnership Projects (PPP) and has taken initiatives to reduce drug prices. The market is expected to exhibit steady growth over the next few years.

1. Insert Cover Image using Slide Master View
Do not distort
Anti-Infective Pharmaceuticals Market - India
September 2011

2. Executive Summary
Anti-infective pharmaceuticals market in India is valued at INR X bn in 20--
Market Market is expected to grow at a CAGR of x% from 20–---
Anti infectives are the largest contributor to domestic sales, contributing around y%
Drivers: Challenges:
Increasing patient population Pricing pressure
Drivers and
Increasing number of vaccine approvals Logistic problems in the vaccine market
Challenges
Increase in health insurances
Introduction of new drugs
Phases of clinical trial
Drug regulation
Approval and licensing of drugs
and patents Patents
Highly fragmented market with large number of players
Major foreign players in the market include Gilead inc, Abbott, Glaxosmithkline etc
Competition
Major domestic companies include Ranbaxy, Cipla, Dr. Reddy’s, Sun Pharmaceuticals, Panacea
Biotech, Torrent Pharmaceuticals among others
Strategic Foray into the adult vaccine market
recommendations Partnership with Governmental and private bodies
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT 2

3. •Introduction
•Market Overview
•Drivers & Challenges
•Government Initiatives
•Drug Regulation and Patents
•Competition
•Strategic Recommendations
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT 3

4. Indian anti-infectives market is expected to witness an
enormous growth over the coming years
Indian Market – Overview Market Size and Growth
• Anti-infectives belong to the acute segment which INR bn
makes up around z% of the total pharmaceutical 200
industry x% x6
150 x5
Anti-infectives are the largest contributor to domestic x4
x3
pharmaceuticals sales, contributing around y% x2
100 x1
Cephalosporins, penicillins and quinolones are key drug
classes among anti-infectives, with a share of around z% of 50
the country’s anti-infectives market 0
• Presently the market has a size of INR X bn, and is 2010 2011e 2012e 2013e 2014e 2015e
expected to grow at a CAGR of x% from 20-----
• In 2010 GSK’s Augmentin was the highest selling drug Top pharmaceutical segments – 2010
with sales of INR Y bn 0 2 4 6 8 10 12 14 16 18
Zifi, Taxim ,Monocef, Mox, Taxim-O , Zinacef and Gerimac %
anti-infectives y1
were the other top selling drugs
CVS y2
• India has emerged as one of the leading vaccine gastro y3
manufacturer in recent times, producing z% of the CNS y4
global health vaccines respiratory y5
Pentaxim, Varivax and Prevenar were the top selling diabetes y6
vaccines in 20-- pain y7
oncology y8
Source:
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT 4

5. Drivers & Challenges – Summary
Drivers Challenges
Increasing patient population Pricing pressure
Increasing number of vaccine Logistic problems in the vaccine
approvals market
Increase in health insurances
Introduction of new drugs
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT 5

6. Government Initiatives – Summary
Changes in tax structure Control programmes
Government
Initiatives
PPP Projects Reduction in drug prices
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT 6

7. Major domestic players in the market (1/9)
Company Snapshot: Company 1
Corporate Information Financial Performance
Revenue Revenue Profit
Headquarters Location A
INR bn INR bn
Profit / Loss
Founded 19-- 100 r4 60
r2 r3
r1
40
Products Product 1, product 2
50
20
Key People Person X– MD
0 0
2008 2009 2010 2011
Business Highlights
• Employing around XX people, Company 1 is India’s largest pharmaceutical company, having manufacturing facilities in
seven countries and serving customers in over YY countries
• In June 20--, the company entered into an alliance with Company X to create an innovator and generic
pharmaceuticals powerhouse
• Company 1 launched anti-infectives such as Product 1 and Product 2 for the first time in India and is trying to promote
the concept of product 3 on a local basis
• Signed an agreement with Company X for manufacturing and marketing 3 new HIV/AIDS drugs in India and
developing countries
• Has been working on an anti-malaria research project since May 20-- to develop cheap anti malarial drugs
Source:
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT 7

8. Thank you for the attention
The Anti-Infective Pharmaceuticals Market – India report is part of Netscribes’ Healthcare
Industry Series.
For more detailed information or customized research requirements please contact:
Tamojit Roy Gagan Uppal
Phone: +91 33 4064 6215 Phone: +91 22 4098 7530
E-Mail: tamojit.roy@netscribes.com E-Mail: gagan.uppal@netscribes.com
Research on India is a product of Netscribes (India) Pvt. Ltd. Research on India is dedicated to disseminating information and providing quick
insights on “hot” industries in India and other emerging markets. Track our new releases and major updates in these industries on
About Netscribes
Netscribes is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &
business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true
value proposition that draws upon a vast knowledge base. Netscribes is a one-stop shop designed to fulfil clients’ profitability and growth
objectives.
Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Research on India,
Netscribes (India) Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the
sole property of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction.
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT 8